SGO 2023 Conference Coverage on VuMedi

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

SGO 2023 Conference Coverage on VuMedi

Videos

Playback speed

10 seconds

SGO 2023 Placebo-Controlled Randomized Phase 3 Trial: Dostarlimab in Combination With Chemo for the Treatment of Primary Advanced or Recurrent Endometrial Cancer

By SGO 2023 Conference Coverage on VuMedi FEATURING Mansoor Raza Mirza

251 views

April 5, 2023

Comments 0

The Role Of Folate Receptor Alpha In Ovarian Cancer

Feat. D. M. O'Malley

Best Practices for the management of ocular adverse events associate…

Feat. K. Lamoreau

Videos

SGO 2023 Updates on Advanced or Recurrent Endometrial Tumors: NGS Co…

SGO 2023 Conference Coverage on VuMedi

S. Lee

88 views

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients Wit…

SGO 2023 Conference Coverage on VuMedi

B. Bockorny

87 views

SGO 2023 GOG 3026 Phase II Trial of Letrozole + Ribociclib in Women …

SGO 2023 Conference Coverage on VuMedi

B. Slomovitz

401 views

Molecular Classification of Mixed Histology Endometrial Cancers

SGO 2023 Conference Coverage on VuMedi

P. Haight

153 views

SGO 2023 Phase 3 UP-NEXT Trial: Upifitamab Rilsodotin, a NaPi2b-Dire…

SGO 2023 Conference Coverage on VuMedi

D. Richardson

117 views

Chemoradiation for Stage IB3 Cervical Cancer

SGO 2023 Conference Coverage on VuMedi

J. Mayadev

551 views

SGO 2023 Placebo-Controlled Randomized Phase 3 Trial: Dostarlimab in…

SGO 2023 Conference Coverage on VuMedi

M. Raza Mirza

251 views

SGO 2023 Primary Ovarian Cancer Patients: Health-Related Quality of …

SGO 2023 Conference Coverage on VuMedi

V. Gushchin

46 views

SGO 2023 Sentinel Lymph Biopsy vs. Full Lymphadenectomy in Endometri…

SGO 2023 Conference Coverage on VuMedi

C. Nahshon

171 views